CAJ | 학술논문

目的：评价不同剂量LB80380治疗慢性乙型肝炎的有效性、安全性及时效性。方法检索各数据库从建库到2014年1月30日发表的有关LB80380治疗慢性乙型肝炎的随机对照试验，应用Meta分析方法对查阅到的5篇随机对照研究进行分析评估。结果①有效率：口服LB8038030 mg·d-1分别与口服60、90、150、240 mg·d-1后的血清HBV DNA变化量相比，差异有统计学意义，其有效率更低。口服LB8038060 mg·d-1与口服150 mg·d-1血清 HBV DNA相比，差异有统计学意义，其有效率更低，其余各组差异均无统计学意义。②时效性：较低剂量 LB8038090mg· d-1与较高剂量150mg·d-1分别治疗慢性乙型肝炎4、12、24和48周的分析结果显示，治疗24周与治疗48周疗效无统计学差异外，其余各组差异均有统计学意义。③不良反应发生率：口服不同剂量 LB80380及口服恩替卡韦0．5 mg· d-1，肌酐清除率差异均无统计学意义。结论 LB8038090、150、240 mg·d-1与其他低剂量相比，其抗病毒效果更好， LB80380治疗24周与治疗48周相比，差异无统计学意义。
목적：평개불동제량LB80380치료만성을형간염적유효성、안전성급시효성。방법검색각수거고종건고도2014년1월30일발표적유관LB80380치료만성을형간염적수궤대조시험，응용Meta분석방법대사열도적5편수궤대조연구진행분석평고。결과①유효솔：구복LB8038030 mg·d-1분별여구복60、90、150、240 mg·d-1후적혈청HBV DNA변화량상비，차이유통계학의의，기유효솔경저。구복LB8038060 mg·d-1여구복150 mg·d-1혈청 HBV DNA상비，차이유통계학의의，기유효솔경저，기여각조차이균무통계학의의。②시효성：교저제량 LB8038090mg· d-1여교고제량150mg·d-1분별치료만성을형간염4、12、24화48주적분석결과현시，치료24주여치료48주료효무통계학차이외，기여각조차이균유통계학의의。③불량반응발생솔：구복불동제량 LB80380급구복은체잡위0．5 mg· d-1，기항청제솔차이균무통계학의의。결론 LB8038090、150、240 mg·d-1여기타저제량상비，기항병독효과경호， LB80380치료24주여치료48주상비，차이무통계학의의。
Objective To assess the efficacy and safety of different doses of LB80380 in the treatment of chronic hepatitis B patients. Methods Five retrieved randomized controlled reseaches refer to the treatment of chronic hepatitis B by different doses of LB80380 before January 30,2014 were subjected to a system evaluation. Results Meta-analyses showed that the reduction rate of blood HBV DNA in patients receiving LB80380 with 30 mg · d-1 was significantly lower than that in patients receiving the doses of 60,90,150 and 240 mg·d-1 . The reduction rate of blood HBV DNA in patients receiving LB80380 with 60 mg·d-1 was significantly lower than that in patients receiving the dose of 150 mg·d-1 ,while no significant difference was observed among other groups. There is no statistical difference in creatinine clearance rate among different doses of LB80380 or entecavir with 0.5 mg·d-1 . Conclusions LB80380 with 90,150 and 240 mg· d-1 tend to have better efficacy and safety profiles compared to LB80380 with 30,60 and 120 mg · d-1;however,there is no remarkable statistical difference of the efficacy between 24 and 48 weeks treatment,and the creatinine clearance rate among different group does not show statistically difference.